SALR Stock Overview
SALUS, Ljubljana, d. d. engages in the provision of distribution, promotion, active sales, and value-added services for the medicinal products, dietary supplements, or medical devices in Slovenia and internationally.
SALUS Ljubljana d. d Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€1,420.00|
|52 Week High||€1,490.00|
|52 Week Low||€1,260.00|
|1 Month Change||-3.40%|
|3 Month Change||2.16%|
|1 Year Change||2.16%|
|3 Year Change||115.15%|
|5 Year Change||195.83%|
|Change since IPO||1,583.18%|
Recent News & Updates
We Like These Underlying Return On Capital Trends At SALUS Ljubljana d. d (LJSE:SALR)
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
With EPS Growth And More, SALUS Ljubljana d. d (LJSE:SALR) Is Interesting
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
These 4 Measures Indicate That SALUS Ljubljana d. d (LJSE:SALR) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
|SALR||SI Healthcare||SI Market|
Return vs Industry: SALR exceeded the SI Healthcare industry which returned -33.1% over the past year.
Return vs Market: SALR exceeded the SI Market which returned -20.7% over the past year.
|SALR Average Weekly Movement||n/a|
|Healthcare Industry Average Movement||4.6%|
|Market Average Movement||3.6%|
|10% most volatile stocks in SI Market||4.3%|
|10% least volatile stocks in SI Market||2.9%|
Stable Share Price: Insufficient data to determine SALR's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine SALR's volatility change over the past year.
About the Company
SALUS, Ljubljana, d. d. engages in the provision of distribution, promotion, active sales, and value-added services for the medicinal products, dietary supplements, or medical devices in Slovenia and internationally. The company offers medicines, medical devices, diagnostic devices, medical supplies, sanitary products, dietary supplements, cosmetic products, pharmaceutical packaging, and other health and well-being related products to pharmacies, hospitals, community health centers, residential homes, veterinary institutions, and other customers. It also provides services, such as warehousing services for medicines and other medicinal products; secondary packaging of medicines and other products; and regulatory services for medicinal products, medical devices, and food supplements.
SALUS Ljubljana d. d Fundamentals Summary
|SALR fundamental statistics|
Is SALR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SALR income statement (TTM)|
|Cost of Revenue||€422.96m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||118.07|
|Net Profit Margin||2.58%|
How did SALR perform over the long term?See historical performance and comparison
4.9%Current Dividend Yield
Is SALR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SALR?
Other financial metrics that can be useful for relative valuation.
|What is SALR's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does SALR's PE Ratio compare to its peers?
|SALR PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
2393 Nippon Care Supply
3154 Medius Holdings
PGC Paragon Care
PHARMA Pharmaniaga Berhad
SALR SALUS Ljubljana d. d
Price-To-Earnings vs Peers: SALR is good value based on its Price-To-Earnings Ratio (12x) compared to the peer average (13.8x).
Price to Earnings Ratio vs Industry
How does SALR's PE Ratio compare vs other companies in the European Healthcare Industry?
Price-To-Earnings vs Industry: SALR is good value based on its Price-To-Earnings Ratio (12x) compared to the European Healthcare industry average (17.2x)
Price to Earnings Ratio vs Fair Ratio
What is SALR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||12x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SALR's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of SALR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SALR (€1420) is trading below our estimate of fair value (€13304.96)
Significantly Below Fair Value: SALR is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is SALUS Ljubljana d. d forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SALUS Ljubljana d. d has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine whether SALUS Ljubljana d. d is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
How has SALUS Ljubljana d. d performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SALR has high quality earnings.
Growing Profit Margin: SALR's current net profit margins (2.6%) are lower than last year (3.2%).
Past Earnings Growth Analysis
Earnings Trend: SALR's earnings have grown significantly by 31.9% per year over the past 5 years.
Accelerating Growth: SALR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SALR had negative earnings growth (-4.3%) over the past year, making it difficult to compare to the Healthcare industry average (19.4%).
Return on Equity
High ROE: SALR's Return on Equity (18%) is considered low.
Discover strong past performing companies
How is SALUS Ljubljana d. d's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: SALR's short term assets (€131.2M) exceed its short term liabilities (€98.5M).
Long Term Liabilities: SALR's short term assets (€131.2M) exceed its long term liabilities (€9.9M).
Debt to Equity History and Analysis
Debt Level: SALR has more cash than its total debt.
Reducing Debt: SALR's debt to equity ratio has increased from 0.7% to 10.8% over the past 5 years.
Debt Coverage: SALR's debt is well covered by operating cash flow (300.2%).
Interest Coverage: SALR earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is SALUS Ljubljana d. d current dividend yield, its reliability and sustainability?
Dividend Score 4/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SALR's dividend (4.93%) is higher than the bottom 25% of dividend payers in the SI market (4.29%).
High Dividend: SALR's dividend (4.93%) is low compared to the top 25% of dividend payers in the SI market (9.15%).
Stability and Growth of Payments
Stable Dividend: SALR's dividend payments have been volatile in the past 10 years.
Growing Dividend: SALR's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (55%), SALR's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (42.1%), SALR's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
SALUS Ljubljana d. d has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
SALUS, Ljubljana, d. d.'s employee growth, exchange listings and data sources
- Name: SALUS, Ljubljana, d. d.
- Ticker: SALR
- Exchange: LJSE
- Founded: 1969
- Industry: Health Care Distributors
- Sector: Healthcare
- Implied Market Cap: €148.213m
- Shares outstanding: 104.38k
- Website: https://www.salus.si
Number of Employees
- SALUS, Ljubljana, d. d.
- Litostrojska cesta 46 A
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/17 00:00|
|End of Day Share Price||2022/08/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.